Insufficient use of menopausal hormone therapy in Swedish women with early or premature menopause caused by bilateral oophorectomy: a register‐based study

Abstract

AbstractObjectiveTo investigate the use of menopausal hormone therapy (MHT) in premenopausal women after bilateral oophorectomy.DesignRetrospective register‐based cohort study.SettingSweden.PopulationSwedish women aged 35–44 years without malignancy who underwent bilateral oophorectomy in 2005–2020 were identified using The Swedish National Quality Register of Gynaecological Surgery (GynOp).MethodsData from GynOp were cross‐linked with data on dispensed drugs extracted from the Swedish Prescribed Drug Register.Main outcome measuresProportion of women dispensed MHT at least once within 1 year after surgery. Repeated treatment episodes were defined, and the proportion of ‘person time’ covered by dispensations was analysed.ResultsIn total, 1231 of all women (n = 1706) were dispensed MHT at some point after surgery, with 1177 women dispensed MHT within 1 year. This proportion increased from 64% in 2005 to 84% in 2019 (p < 0.001). In the total population, 4537 ‘treatment years’ transpired, corresponding to 43% of the mean time covered. In women dispensed MHT within 1 year, the proportion of time covered was 63%.ConclusionsOnly 69% of all women without malignancy of any kind who underwent bilateral oophorectomy were dispensed MHT within 1 year after surgery, and the duration of treatment was limited. It is important to study further the reasons behind the low dispensation rate in this group to increase adherence to current treatment guidelines, improve quality of life, and avoid increased morbidity and mortality.